Advertisement

HGS selected to supply additional doses

ROCKVILLE, Md., July 22 (UPI) -- The U.S. government has awarded Human Genome Sciences Inc. a follow-on contract to support the counter biological terrorism program Project BioShield.

U.S. company HGS was contracted to deliver 45,000 additional doses of its raxibacumab ABthrax inhalation anthrax treatment for the U.S. Strategic National Stockpile. The contract, worth approximately $151 million, is part of the U.S. government's ongoing counter biological terrorism initiatives.

Advertisement

Officials say the deliveries of the raxibacumab will take place over a three-year period in support of Project BioShield.

"We are very pleased to receive this second purchase order for raxibacumab and look forward to the continued progress of our partnership with the U.S. government under Project BioShield to help strengthen America's arsenal against bio-terrorism," Thomas Watkins, HGS president and chief executive officer, said in a statement.

Latest Headlines

Advertisement
Advertisement

Follow Us

Advertisement